Loss of lkb1 Expression Reduces the Latency of ErbB2-Mediated Mammary Gland Tumorigenesis, Promoting Changes in Metabolic Pathways

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Andrade Vieira, Rafaela ^a   Xu, Zhaolin ^a   Colp, Patricia ^a   Marignani, Paola A ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AZD 8055; CARNITINE; CHOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FUMARIC ACID; GLUTAMIC ACID; GLUTATHIONE; GLYCINE; GLYCOLYTIC ENZYME; LACTATE DEHYDROGENASE; LACTIC ACID; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHIONINE; PHOSPHOETHANOLAMINE; PROTEIN KINASE B; PROTEIN KINASE LKB1; PROTEIN S6; PYRUVATE DEHYDROGENASE; TORIN 1; UNCLASSIFIED DRUG; VALINE;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METABOLITE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; ONCOGENE NEU; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; WESTERN BLOTTING;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; MAMMARY NEOPLASMS, ANIMAL; METABOLIC NETWORKS AND PATHWAYS; MICE; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; TOR SERINE-THREONINE KINASES;

EID: 84874333622     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056567     Document Type: Article

References (40)

1. Avizienyte E, Loukola A, Roth S, Hemminki A, Tarkkanen M, et al. (1999) LKB1 somatic mutations in sporadic tumors. Am J Pathol 154: 677-681.
2. Lim W, Hearle N, Shah B, Murday V, Hodgson SV, et al. (2003) Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer 89: 308-313.
3. Fenton H, Carlile B, Montgomery E, Carraway H, Herman J, et al. (2006) LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol 14: 146-153.
4. Nath-Sain S, Marignani P, (2009) LKB1 catalytic activity contributes to ERalpha activity. Molecular Biology of the Cell 20: 2785-2795.
5. Marignani P, Sanchez-Cespedes M (2010) The tumour suppressor role of LKB1 in human cancer. In: Lazo PA, editor. Emerging Signalling Pathways in Tumor Biology: Transworld Research Network. 71-94.
6. Baas AF, Boudeau J, Sapkota GP, Smit L, Medema R, et al. (2003) Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. Embo J 22: 3062-3072.
7. Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, et al. (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23: 833-843.
8. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, et al. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 101: 3329-3335.
9. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL, (2004) Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18: 1533-1538.
10. Sarbassov DD, Ali SM, Sabatini DM, (2005) Growing roles for the mTOR pathway. Current Opinion in Cell Biology 17: 596-603.
11. Sakamoto K, McCarthy A, Smith D, Green KA, Grahame Hardie D, et al. (2005) Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J 24: 1810-1820.
12. McCarthy A, Lord C, Savage K, Grigoriadis A, Smith D, et al. (2009) Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation. The Journal of Pathology 219: 306-316.
13. Partanen JI, Tervonen TA, Myllynen M, Lind E, Imai M, et al. (2012) Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity. Proceedings of the National Academy of Sciences 109: E388-E397.
14. Scott KD, Nath-Sain S, Agnew MD, Marignani PA, (2007) LKB1 Catalytically Deficient Mutants Enhance Cyclin D1 Expression. Cancer Res 67: 5622-5627.
15. Lodén M, Stighall M, Nielsen NH, Roos G, Emdin SO, et al. (2002) The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 21: 4680-4690.
16. Varley J, Swallow JE, Brammar WJ, Whittaker JL, Ra W, (1987) Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1: 423-430.
17. Li B, Rosen JM, McMenamin-Balano J, Muller WJ, Perkins AS, (1997) neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol 17: 3155-3163.
18. Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127.
19. Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, et al. (2012) Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clinical Cancer Research 18: 6784-6791.
20. Schade B, Rao T, Dourdin N, Lesurf R, Hallett M, et al. (2009) PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis. Journal of Biological Chemistry 284: 19018-19026.
21. Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, et al. (2002) Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419: 162-167.
22. Mercier P, Lewis M, Chang D, Baker D, Wishart D, (2011) Towards automatic metabolomic profiling of high-resolution one-dimensional proton NMR spectra. Journal of Biomolecular NMR 49: 307-323.
23. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, et al. (2009) An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1. J Biol Chem 284: 8023-8032.
24. Katajisto P, Vaahtomeri K, Ekman N, Ventela E, Ristimaki A, et al. (2008) LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat Genet 40: 455-459.
25. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99.
26. Garcia-Martinez JM, Wullschleger S, Preston G, Guichard S, Fleming S, et al. (2011) Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br J Cancer 104: 1116-1125.
27. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702-4711.
28. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, et al. (2009) AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity. Cancer Research 70: 288-298.
29. Carretero J, Medina PP, Blanco R, Smit L, Tang M, et al. (2007) Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 26: 1616-1625.
30. Eskens FALM, Mom CH, Planting AST, Gietema JA, Amelsberg A, et al. (2007) A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98: 80-85.
31. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
32. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, et al. (2011) Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes & Development 25: 1041-1051.
33. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, et al. (2010) Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1. Molecular Cell 39: 171-183.
34. Shaw RJ, Lamia KA, Vasquez D, Koo S-H, Bardeesy N, et al. (2005) The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin. Science 310: 1642-1646.
35. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Sci Signal 324: 1029.
36. Albrecht S, Barata A, Großhans J, Teleman A, Dick T, (2011) In Vivo Mapping of Hydrogen Peroxide and Oxidized Glutathione Reveals Chemical and Regional Specificity of Redox Homeostasis. Cell Metabolism 14: 819-829.
37. Weigelt B, Warne PH, Downward J, (2011) PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30: 3222-3233.
38. Holt SV, Logie A, Davies BR, Alferez D, Runswick S, et al. (2012) Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055). Cancer Research 72: 1804-1813.
39. Gatenby RA, Gawlinski ET, (1996) A Reaction-Diffusion Model of Cancer Invasion. Cancer Research 56: 5745-5753.
40. Zha X, Wang F, Wang Y, He S, Jing Y, et al. (2011) Lactate Dehydrogenase B Is Critical for Hyperactive mTOR-Mediated Tumorigenesis. Cancer Research 71: 13-18.